狗万官网在哪里找Esco Lifesciences Group and Its Affiliate, Esco Aster, Signs a Memorandum of Understanding with the Medical and Pharmaceutical Industry Technology Development Center (PITDC) Taiwan

Key Points:

1. Esco Aster's collaboration with PITDC Taiwan signifies a strategic alliance aimed at advancing manufacturing standards and consolidating Taiwan's position in the burgeoning cell therapy industry.
2. The partnership involves combining PITDC's stem cell innovation process with Esco's advanced bioreactor technology, resulting in an important advancement in international cooperation in stem cell production and bioreactor technology.
3. The collaboration aims to accelerate the development of new stem cell therapies, particularly addressing diseases with high unmet needs such as fibrotic conditions, organ transplantation, and bone marrow fibrosis.This collaboration holds the potential to bring new hope for patients and significantly impact medical advancements.

SINGAPORE—13 March 2024 - In response to the next wave of advanced manufacturing as well as cGMP Standards in the cell therapy industry 4.0 and to consolidate Taiwan's competitive advantage in the burgeoning cell therapy industry, the Medical Technology Development Center (MTPDC) has signed a Memorandum of Understanding (MOU) with ESCO ASTER.

The MOU was signed by Mr.Xiangliang (XL), Lin CEO of ESCO ASTER (right X), and Mr.Ping-Lun Chiang, Director of the Department of Medical Engineering, Pharmaceutical Technology Center (left X).

The Center for Pharmaceutical Industry and Technology Development announced that it has signed a Memorandum of Understanding (MOU) with ESCO Life Sciences Group (ESCO), a Singapore-based company, to jointly invest in the development of 3D Tide Motion bioreactors to produce cGMP 3D mesenchymal stromal cells.

This technology has shown significant potential in the treatment of diseases such as organ transplantation anti-rejection and bone marrow fibrosis, which can improve the survival rate after transplantation and reduce the dependence on anti-rejection drugs.

In an animal model of bone marrow fibrosis, the technology is more effective than existing clinical drugs such as Jakavi in alleviating the symptoms of the disease.The Center has completed the validation and patent application of this technology.狗万官网在哪里找Esco Lifesciences Group and affiliate Esco Aster have complete GLP and cGMP-compliant facilities, and its tidal bioreactor has been widely used in international human and animal vaccine production, secretomes, cancer diagnostics, and exosomes.

狗万官网在哪里找The Center will cooperate with Esco Lifesciences Group to scale up the production of new cellular drug products, and Esco Aster will help the Center to attract capital from Southeast Asia and facilitate the international cooperation for the export of the whole clinical protocol for advanced medicinal therapies or otherwise known as cell, tissue or gene therapy products (CTGTP).

This collaboration is expected to accelerate the development of new stem cell therapies and bring new hope for the treatment of related diseases with high unmet need in fibrotic conditions such as myelofibrosis, cardiac stroke regeneration to aid recovery as well as post organ transplant for liver, kidney, and other organ transplant.

About Esco Aster

Esco Aster is a contract research development and manufacturing organization (CRDMO) founded and deeply rooted by scientists enabling fellow scientists to translate their bench work into life-saving diagnostics, medicines, therapies, cosmeceuticals, and cellular agriculture, at affordable prices for self-sufficiency of the country.We make complex manufacturing simple via our proprietary best-in-class continuous manufacturing platforms providing a reliable and linearly scalable outcome.Learn more atwww.escoaster.comand connect withEsco Aster on LinkedIn

狗万官网在哪里找About Esco Lifesciences Group

狗万官网在哪里找is a world-leading life science company with a diversified portfolio and sales in over 100 countries.As a manufacturer of laboratory and biopharma equipment, and IVF medical devices, Esco offers tailored solutions that fit the needs of laboratories in various industries.

狗万官网在哪里找Esco Lifesciences contributes to meet the challenges of the 21st century with a diverse range of business units.The company continuously innovates its products to help the clinical and industrial laboratories achieve successful conclusions in research and development, quality control, and analysis.We continue to provide reliable world-class equipment to help pharmaceutical companies make their products safer and more cost-effective.And with the increasing demand of the IVF industry, we have developed efficient ART equipment to enable equitable access to infertility care.

About PITDC

The PITDC Taiwan is a leading institution driving innovation in the medical and pharmaceutical sectors.Through collaborations with industry and academia, PITDC develops cutting-edge technologies to address healthcare challenges.With a focus on research, development, and commercialization, PITDC supports Taiwan's medical industry growth.Through strategic partnerships and state-of-the-art facilities, PITDC translates scientific discoveries into practical applications.Positioned as a key player in Taiwan's healthcare ecosystem, PITDC fosters innovation and partnerships to advance medical technologies, benefiting global healthcare outcomes.Visit PITDC'sofficial websitefor more information.

*Adapted from:https://healthmedia.com.tw/main_detail.php?id=62277